Search

Displaying results 1991 - 2000 of 10000 in total
  1. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15606,L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour. … [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.

  2. Drug

    Acer saccharum pollen

    go.drugbank.com/drugs/DB10369
    Approved

    Acer saccharum pollen is mainly used in allergenic testing.

    Mixtures: Maple/box Elder, Maple-Box Elder Pollen MixCategories: Non-Standardized Pollen Allergenic Extract
  3. Drug

    Lonapegsomatropin

    go.drugbank.com/drugs/DB16220
    ApprovedInvestigational

    [L36380,L10971] Lonapegsomatropin was granted FDA approval on 25 August 2021.[L36380] It was later approved by the European Commission on 13 January 2022.[L39900]

  4. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.

    Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase
  5. Drug

    Eplerenone

    go.drugbank.com/drugs/DB00700
    ApprovedInvestigational

    regulatory feedback of aldosterone on renin secretion. … Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative

  6. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and … By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV.

  7. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]

  8. Drug

    Poa compressa pollen

    go.drugbank.com/drugs/DB10713
    Approved

    Poa compressa pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Inland Grasses, Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  9. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803]

  10. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    in the first trimester [A33031]. … Cocoa butter is an edible natural fat obtained from the _Theobroma cocoa_ seeds that is predominantly found in dark chocolate [A33033].

    Products: Coconut Cosmetics 3-in-1 Serum